stockrowBio-Rad Laboratories, Inc.
BIO.B Healthcare Medical Devices
Bio-Rad Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 billion, up 0.65% from fiscal 2024.
- Revenue
- +0.52%
- EPS
- +234.9%
- Free cash flow
- +8.07%
- Total debt
- +0.11%
Quarter to September 2026, against a year earlier
Follow BIO.B
Alert me
Bio-Rad Laboratories, Inc. (BIO.B) EV/FCF
As of 27 October 2026, Bio-Rad Laboratories, Inc. (BIO.B) trades at a EV/FCF of 29.5×. Over the past ten years it has ranged from −13,066× (August 2017) to 534× (June 2017); the current reading is higher than 25% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 21.6× | (27.81%) |
| FY2024 | 29.9× | (26.38%) |
| FY2023 | 40.6× | (70.28%) |
| FY2022 | 137× | 255.98% |
| FY2021 | 38.4× | 14.38% |
| FY2020 | 33.6× | 19.46% |
| FY2019 | 28.1× | (30.32%) |
| FY2018 | 40.3× | — |
| FY2017 | −611× | — |
| FY2016 | 66.6× | 32.56% |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | 28.3× | 33.81% |
| Jun 2026 | 21.2× | 6.53% |
| Mar 2026 | 19.9× | (7.99%) |
| Dec 2025 | 21.6× | (1.84%) |
| 43 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| SNN Smith & Nephew SNATS, Inc. compare | 8.3× |
| GMED Globus Medical, Inc. compare | 14.9× |
| BIO Bio-Rad Laboratories, Inc. compare | 28.8× |
| BIO.B Bio-Rad Laboratories, Inc. | 29.5× |
| BRKR Bruker Corporation compare | 38.8× |
| PODD Insulet Corporation compare | 48.0× |
| TXG 10x Genomics compare | 58.9× |
| PEN Penumbra, Inc. compare | 59.8× |
| GKOS Glaukos Corporation compare | 360× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on BIO.B
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement